EVAapplication/xmlftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1435562/MP-MGH-U3_somatic_standardized_fixed.vcf.gz.csiftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1435562/UCSD-MGH-U3_somatic_standardized_fixed.vcf.gzftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1435562/UCSD-MGH-U3_somatic_standardized_fixed.vcf.gz.csiftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1435562/MP-MGH-U3_somatic_standardized_fixed.vcf.gzftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1435562/MP-MGH-U3_somatic_standardized_fixed.vcf.csiftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1435562/UCSD-MGH-U3_somatic_standardized_fixed.vcf.csiprimaryOK200Exome SequencingGenomicsShenzhen University, South China HospitalIlluminaHomo Sapienshttps://www.ebi.ac.uk/eva/?eva-study=PRJNA1435562EVAfalseRecurrence in the chemotherapy regimen of bladder carcinoma originates from quiescent epidermoid-like cellsCancer relapse upon chemotherapy remains the primary challenge in cancer treatment. By integrating high-resolution CRISPR/Cas9-based evolving lineage tracing with single-cell RNA sequencing in mice, we tracked the evolution of bladder carcinoma in the presence or absence of chemotherapy. We found that a cell population exhibiting an epidermoid-like cell state was able to survive chemotherapy. These epidermoid-like cells left the quiescent state to initiate relapse, generating histologically distinct tumors through different evolutionary routes involving specific transcriptional changes. The plasticity of epidermoid-like cells and alterations in plasticity patterns during evolution have shaped the phenotypes of relapsed tumors. Integrated analyses revealed that Insulin-like growth factor-binding protein 5 was a key co-regulator of aggressive progression and squamous features in bladder carcinoma. Impeding Insulin-like growth factor-binding protein 5 expression suppressed the chemoresistance and malignant behaviors of relapsed tumors. Our study deciphers key events and evolutionary dynamics during the natural progression and recurrence of bladder carcinoma. It offers a viable therapeutic approach to overcome the refractoriness of relapsed bladder carcinoma to conventional chemotherapy.2026-03-12PRJNA14355629606